CERO has 36-month beta value of -0.40.
The public float for CERO is 6.98M, and currently, short sellers hold a 1.65% ratio of that float. The average trading volume of CERO on June 18, 2024 was 1.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CERO) stock’s latest price update
The stock of CERo Therapeutics Holdings Inc. (NASDAQ: CERO) has decreased by -6.14 when compared to last closing price of 0.35. Despite this, the company has experienced a -55.91% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-13 that Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
CERO’s Market Performance
CERo Therapeutics Holdings Inc. (CERO) has seen a -55.91% fall in stock performance for the week, with a -70.14% decline in the past month and a -86.31% plunge in the past quarter. The volatility ratio for the week is 50.04%, and the volatility levels for the past 30 days are at 20.85% for CERO. The simple moving average for the past 20 days is -59.72% for CERO’s stock, with a -95.23% simple moving average for the past 200 days.
CERO Trading at -72.63% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.43% of loss for the given period.
Volatility was left at 20.85%, however, over the last 30 days, the volatility rate increased by 50.04%, as shares sank -69.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.92% lower at present.
During the last 5 trading sessions, CERO fell by -56.20%, which changed the moving average for the period of 200-days by -96.99% in comparison to the 20-day moving average, which settled at $0.7789. In addition, CERo Therapeutics Holdings Inc. saw -97.01% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CERO
Equity return is now at value -1708.01, with -33.39 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.47.
Conclusion
To put it simply, CERo Therapeutics Holdings Inc. (CERO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
